Friedwald Center For Dialysis is a medicare approved dialysis facility center in New City, New York and it has 9 dialysis stations. It is located in Rockland county at 475 New Hempstead Road, New City, NY, 10956. You can reach out to the office of Friedwald Center For Dialysis at (845) 678-2000. This dialysis clinic is run as an Independent entity i.e it is not owned by any chain organization. Friedwald Center For Dialysis has the following ownership type - Profit. It was first certified by medicare in August, 2013. The medicare id for this facility is 332696 and it accepts patients under medicare ESRD program.
| Name | Friedwald Center For Dialysis |
|---|---|
| Location | 475 New Hempstead Road, New City, New York |
| No. of Dialysis Stations | 9 |
| Medicare ID | 332696 |
| Managed By | Independent |
| Ownership Type | Profit |
| Late Shifts | Yes |
| 475 New Hempstead Road, New City, New York, 10956 | |
| (845) 678-2000 | |
News Archive
Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, today announced the initiation of a randomized, open-label, four-way cross-over pharmacokinetics study to evaluate the bioavailability of Epanova, Omthera's lead compound for the treatment of very high triglycerides, in comparison to Lovaza, the leading prescription Omega-3.
Why are men at greater risk than women for more severe symptoms and worse outcomes from COVID-19 regardless of age?
A newly published study on patients with primary and secondary liver cancer shows how Perspectum's non-invasive MRI technology can help predict those at increased risk of poor surgical outcomes, potentially reducing healthcare costs by shortening length of hospital stay.
Cancer Research UK and Cancer Research Technology - the charity's development and commercialisation arm - have partnered with Centella Therapeutics, Inc. of Palo Alto, California, to develop, manufacture and trial a promising new drug, CEN-209 in cancer patients with solid tumours.
› Verified 3 days ago
| NPI Number | 1306110655 |
| Doing Business As | Friedwald Center For Dialysis Llc |
| Address | 475 New Hempstead Rd New City, New York, 10956 |
| Phone Number | (845) 678-2000 |
News Archive
Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, today announced the initiation of a randomized, open-label, four-way cross-over pharmacokinetics study to evaluate the bioavailability of Epanova, Omthera's lead compound for the treatment of very high triglycerides, in comparison to Lovaza, the leading prescription Omega-3.
Why are men at greater risk than women for more severe symptoms and worse outcomes from COVID-19 regardless of age?
A newly published study on patients with primary and secondary liver cancer shows how Perspectum's non-invasive MRI technology can help predict those at increased risk of poor surgical outcomes, potentially reducing healthcare costs by shortening length of hospital stay.
Cancer Research UK and Cancer Research Technology - the charity's development and commercialisation arm - have partnered with Centella Therapeutics, Inc. of Palo Alto, California, to develop, manufacture and trial a promising new drug, CEN-209 in cancer patients with solid tumours.
› Verified 3 days ago
| Dialysis patients with Hemoglobin data | 50 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 42 |
News Archive
Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, today announced the initiation of a randomized, open-label, four-way cross-over pharmacokinetics study to evaluate the bioavailability of Epanova, Omthera's lead compound for the treatment of very high triglycerides, in comparison to Lovaza, the leading prescription Omega-3.
Why are men at greater risk than women for more severe symptoms and worse outcomes from COVID-19 regardless of age?
A newly published study on patients with primary and secondary liver cancer shows how Perspectum's non-invasive MRI technology can help predict those at increased risk of poor surgical outcomes, potentially reducing healthcare costs by shortening length of hospital stay.
Cancer Research UK and Cancer Research Technology - the charity's development and commercialisation arm - have partnered with Centella Therapeutics, Inc. of Palo Alto, California, to develop, manufacture and trial a promising new drug, CEN-209 in cancer patients with solid tumours.
› Verified 3 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 89 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 641 |
| Percentage of adult patients getting regular hemodialysis at the center | 98 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, today announced the initiation of a randomized, open-label, four-way cross-over pharmacokinetics study to evaluate the bioavailability of Epanova, Omthera's lead compound for the treatment of very high triglycerides, in comparison to Lovaza, the leading prescription Omega-3.
Why are men at greater risk than women for more severe symptoms and worse outcomes from COVID-19 regardless of age?
A newly published study on patients with primary and secondary liver cancer shows how Perspectum's non-invasive MRI technology can help predict those at increased risk of poor surgical outcomes, potentially reducing healthcare costs by shortening length of hospital stay.
Cancer Research UK and Cancer Research Technology - the charity's development and commercialisation arm - have partnered with Centella Therapeutics, Inc. of Palo Alto, California, to develop, manufacture and trial a promising new drug, CEN-209 in cancer patients with solid tumours.
› Verified 3 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Friedwald Center For Dialysis with elevated calcium levels.
| Patients with hypercalcemia | 93 |
| Hypercalcemia patient months | 657 |
| Patients with Serumphosphor | 108 |
| Patients with Serumphosphor less than 3.5 mg/dL | 12 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 38 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 32 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 13 |
| Patients with Serumphosphor greater than 7 mg/dL | 4 |
News Archive
Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, today announced the initiation of a randomized, open-label, four-way cross-over pharmacokinetics study to evaluate the bioavailability of Epanova, Omthera's lead compound for the treatment of very high triglycerides, in comparison to Lovaza, the leading prescription Omega-3.
Why are men at greater risk than women for more severe symptoms and worse outcomes from COVID-19 regardless of age?
A newly published study on patients with primary and secondary liver cancer shows how Perspectum's non-invasive MRI technology can help predict those at increased risk of poor surgical outcomes, potentially reducing healthcare costs by shortening length of hospital stay.
Cancer Research UK and Cancer Research Technology - the charity's development and commercialisation arm - have partnered with Centella Therapeutics, Inc. of Palo Alto, California, to develop, manufacture and trial a promising new drug, CEN-209 in cancer patients with solid tumours.
› Verified 3 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 100 |
| Patient months included in arterial venous fistula and catheter summaries | 612 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 73 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 11 |
News Archive
Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, today announced the initiation of a randomized, open-label, four-way cross-over pharmacokinetics study to evaluate the bioavailability of Epanova, Omthera's lead compound for the treatment of very high triglycerides, in comparison to Lovaza, the leading prescription Omega-3.
Why are men at greater risk than women for more severe symptoms and worse outcomes from COVID-19 regardless of age?
A newly published study on patients with primary and secondary liver cancer shows how Perspectum's non-invasive MRI technology can help predict those at increased risk of poor surgical outcomes, potentially reducing healthcare costs by shortening length of hospital stay.
Cancer Research UK and Cancer Research Technology - the charity's development and commercialisation arm - have partnered with Centella Therapeutics, Inc. of Palo Alto, California, to develop, manufacture and trial a promising new drug, CEN-209 in cancer patients with solid tumours.
› Verified 3 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 81 |
| Hospitalization Rate in facility | 226.5 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 347.4 |
| Hospitalization Rate: Lower Confidence Limit | 151.1 |
News Archive
Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, today announced the initiation of a randomized, open-label, four-way cross-over pharmacokinetics study to evaluate the bioavailability of Epanova, Omthera's lead compound for the treatment of very high triglycerides, in comparison to Lovaza, the leading prescription Omega-3.
Why are men at greater risk than women for more severe symptoms and worse outcomes from COVID-19 regardless of age?
A newly published study on patients with primary and secondary liver cancer shows how Perspectum's non-invasive MRI technology can help predict those at increased risk of poor surgical outcomes, potentially reducing healthcare costs by shortening length of hospital stay.
Cancer Research UK and Cancer Research Technology - the charity's development and commercialisation arm - have partnered with Centella Therapeutics, Inc. of Palo Alto, California, to develop, manufacture and trial a promising new drug, CEN-209 in cancer patients with solid tumours.
› Verified 3 days ago
The rate of readmission show you whether patients who were being treated regularly at Friedwald Center For Dialysis were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 33.7 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 43.2 |
| Readmission Rate: Lower Confidence Limit | 25 |
News Archive
Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, today announced the initiation of a randomized, open-label, four-way cross-over pharmacokinetics study to evaluate the bioavailability of Epanova, Omthera's lead compound for the treatment of very high triglycerides, in comparison to Lovaza, the leading prescription Omega-3.
Why are men at greater risk than women for more severe symptoms and worse outcomes from COVID-19 regardless of age?
A newly published study on patients with primary and secondary liver cancer shows how Perspectum's non-invasive MRI technology can help predict those at increased risk of poor surgical outcomes, potentially reducing healthcare costs by shortening length of hospital stay.
Cancer Research UK and Cancer Research Technology - the charity's development and commercialisation arm - have partnered with Centella Therapeutics, Inc. of Palo Alto, California, to develop, manufacture and trial a promising new drug, CEN-209 in cancer patients with solid tumours.
› Verified 3 days ago